Tissue Regenix Group Regulatory News (TRX)

DATE: 2 April, 2013

Tissue Regenix makes another senior appointment to its US subsidiary

 Donald Hohne recruited as Vice President of Sales Tissue Regenix USA Inc.

Tissue Regenix ('TRX'), the regenerative medical device company, has appointed Donald M Hohne as Vice President of Sales at its US subsidiary Tissue Regenix USA Inc. Donald will work alongside Greg Bila, President of Tissue Regenix USA Inc to drive forward the commercialisation strategy for Tissue Regenix dCELL® technology platform in North America.

Donald joins Tissue Regenix USA Inc. from Bone Bank Allografts, a distributor of bone and soft tissue allografts, where he has served as Director of Business Development since 2008. Prior to that Donald was director of Government Affairs at Kinetic Concepts Inc ('KCI') a global medical technology company where he worked with members of Congress to inform the formation of public health policy.

Greg Bila, President Tissue Regenix USA Inc commented: "We are extremely pleased to have secured the services of Donald Hohne. He brings with him a proven track record in business development; establishing new market opportunities and securing sales with Fortune 500 and mid-market orthopaedic companies. This is an exciting time for Tissue Regenix USA Inc and Donald will be a key figure in driving forward our strategy for growth."

Donald Hohne, Vice President of Sales Tissue Regenix USA Inc said: "I am delighted to be joining Tissue Regenix USA Inc at the start of the company's journey. I am excited by the potential possibilities that are presented by the dCELL® technology platform which will be a welcome offering for the treatment of number of diseases and conditions."

Tissue Regenix established its US subsidiary in November 2012 where it plans to use its patented dCELL® technology to target a number of areas. Work is focusing initially on applying the dCELL® technology to treat a number of chronic diseases but, over time, it could be developed for other applications including vascular repair, heart valve replacement and knee repair.

Antony Odell, Managing Director of Tissue Regenix Group plc said: "This is a great time to be welcoming Donald to Tissue Regenix and his appointment represents another significant step in our growth and development. The United States presents an opportunity to establish our dCELL® technology platform in a market potentially worth hundreds of millions of dollars, and it is a testament to our proposition that we are able to attract people of Donald's Calibre and experience."

ENDS

For Further Information

Tissue Regenix USA Inc: 001 210 347 8302

Greg Bila

Tissue Regenix Group plc: 01904 435 176

Antony Odell

Newgate Communications 02076 806550

Alistair Kellie 07801 234598

Andrew Adie 07970 256512

Martin Greig 07584 221513

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®) technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States- 'Tissue Regenix USA', as part of its commercialisation strategy for its dCELL® technology platform.